Tag Archives: Novartis

Imatinib India News aggregation

[Business Line] [SC Order] [Money control] In a latest order by SC India, the Novartis imatinib case will be listed “before a Bench of one where Hon’ble Mr. Justice Dalveer Bhandari is not a member“.

Posted in Daily interesting IP news | Tagged , , | Leave a comment

Deferacirox-composition-pregrant oppoisition-india

A new pre grant opposition decision is uploaded in IPO site. Application NO: 593/CHENP/2005 is assigned to Novartis and Titled “Dispersible tablets comprising deferacirox”. This application is opposed by Cipla under 25(1). This application is refused under lack of inventive … Continue reading

Posted in Patent case | Tagged , , , | Leave a comment

Alcon – Olopatadine – Apotex – 5641805

[Novartis Press Release] [Bloomberg] Alcon/Novartis announced that they won the patent infringement case of 5,641,805 against Apotex in the US District Court for the Southern District of Indiana and the product is Patanol (olopatadine hydrochloride ophthalmic solution). The case-involved was filed on Nov … Continue reading

Posted in Patent case | Tagged , , , , | 1 Comment

Novartis-Imatinib-India case

[Business Standard] The Supreme Court will start final hearing next month on a plea by Swiss pharma firm Novartis AG challenging the order of an appellate board, which upheld the government’s denial of patent to its blood cancer drug Glivec. … Continue reading

Posted in Patent case | Tagged , , , , | 1 Comment

Novartis sues Medimmune, Biogen and Alexion

[Bloomberg] Novartis sues Medimmune (subsidiary of astrazeneca), Biogen and Alexion pharmaceuticals on US patent 5688688. The target products are AstraZeneca’s Synagisrespiratory treatment; Biogen’s Tysabri for multiple sclerosis; and Alexion’s Soliris, used to treat a life-threatening form of anemia View complaint on prior smart Filed on … Continue reading

Posted in Patent case | Tagged , , , , , , , | Leave a comment